IP Verse

Esteve Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Esteve Pharmaceuticals opposed by its competitors

Explore Esteve Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2817000
Aug 4, 2021Oral Pharmaceutical Compositions Of Dabigatran Etexilate4

Latest publications and patents of Esteve Pharmaceuticals New

Explore the latest publications and patents granted to Esteve Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Oct 21, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Esteve Pharmaceuticals

EP2817000
Aug 4, 2021Oral Pharmaceutical Compositions Of Dabigatran EtexilateGranted And Under Opposition
EP2254579
Jan 10, 2018Use Of Compounds Binding To The Sigma Receptor Ligands For The Treatment Of Neuropathic Pain Developing As A Consequence Of ChemotherapyNo Opposition Filed Within Time Limit

Latest PTAB cases involving Esteve Pharmaceuticals

Discover the latest PTAB cases involving Esteve Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Esteve Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ESTEVE PHARMACEUTICALS - 4 - -
AERA27 - - -
GLENMARK PHARMACEUTICALS EUROPE12 - - -
HAMM & WITTKOPP112 - - -